Preclinical in vitro and in vivo evaluation of [ 11 C]ORM-13070 as PET ligand for alpha-2C adrenergic receptor occupancy using PET imaging in non-human primates

Abstract

This paper describes the preclinical validation of the radioligand [¹¹C]ORM-13070 and its tritiated analog for addressing selectivity and occupancy of the selective alpha-2C adrenergic receptor (α_2CR) antagonist BAY 292 in the cynomolgus brain. BAY 292 is a novel drug candidate being developed for the treatment of obstructive sleep apnea (OSA) via binding to central α_2CR. In vitro autoradiography studies with sections from non-diseased post-mortem human caudate revealed an excellent specific binding window (>80%) using [³H]ORM-13070. BAY 292 bound to the same binding site as [³H]ORM-13070 and generated a good specific binding signal, with greater selectivity for α_2CR. In non-human primates in vivo, [¹¹C]ORM-13070 demonstrated a reversible behavior, with uptake at baseline highest in striatum (putamen, caudate, ventral striatum, and pallidum) and low in the cerebellar cortex, consistent with the known distribution of the α_2CR. A dose dependent increase in receptor occupancy after BAY 292 administration was observed, confirming BBB penetration and target engagement. The estimated EC₅₀ for BAY 292 is 33.39 ± 11.91 ng/mL. This study aimed to demonstrate the suitability of [¹¹C]ORM-13070 as a PET-radioligand for the study of α_2CR in the non-human primate brain, and to pave the way for future clinical PET tracer studies with BAY 292.

Keywords

alpha-2C adrenergic receptor non-human primate ORM-13070 positron emission tomography receptor occupancy

Introduction

α_2C adrenergic receptors (α_2CR) belong to the family of G-protein coupled receptors. Besides the different α₁-adrenergic receptors, α₂-adrenergic receptors can be divided into three homologous subtypes (α_2A, α_2B and α_2C). They play an important physiological role, mainly in the cardiovascular system and in the central nervous system. α_2A- and α_2CR are the main auto receptors involved in presynaptic feedback inhibition of noradrenaline in the central nervous system, regulating the release of noradrenaline from central noradrenergic neurons.¹ Disturbed noradrenaline function has been implicated in many neuropsychiatric and neurodegenerative disorders; in fact, many of the currently used treatments for depression and attention deficit/hyperactivity disorder (ADHD) are based on modulating the synaptic availability of noradrenaline.² Thus, the modulation of noradrenaline release via the adjustment of α_2CR activity is considered a potential therapeutic target for a number of CNS disorders including depression, psychosis and neurodegeneration.³

Several radioligands have been described for the characterization of α₂R, e.g. [¹¹C]-MBF and [¹¹C]-JP-1302, but brain penetration is limited.⁴ In contrast, the radiolabeled PET tracer [¹¹C]ORM-13070 has been designed for the imaging of α_2CR in the brain. Its preclinical evaluation showed promising results in atipamezole pretreated rats and α_2CR knockout mice.⁵ ORM-13070 has also been successfully used to investigate amphetamine-induced changes in rat brain sections and in monkey brains.⁶ Key human studies have explored its radiometabolism, plasma pharmacokinetics and distribution⁷ and its suitability as a PET tracer in the clinical setting.^8
–10 Further research has expanded the potential uses of ORM-13070. One study investigated the tracers’ ability to assess receptor occupancy by the α_2CR-antagonist ORM-12741, providing translational validation of target engagement in both animal models and human subjects.¹¹ Another application of ORM-13070 is in monitoring noradrenaline release in the brain, a critical aspect in the study of mood disorders and stress responses.¹² Overall, ORM-13070 is a promising PET tracer that has shown good brain penetration and selectivity for the α_2CR,^5,13 however, it has not been fully characterized via kinetic modeling.

As BAY 292 is a selective α_2CR antagonist currently in clinical development for the treatment of obstructive sleep apnea (OSA), it served as a suitable tool compound for further optimization towards an improved application of the PET ligand [¹¹C]ORM-13070 in vivo. In this manuscript, we describe a series of in vitro autoradiography experiments conducted to confirm that BAY 292 binds to the same binding site as the PET ligand, as well as in vivo target occupancy studies using [¹¹C]ORM-13070 in non-human primates, aiming to further de-risk the development of the drug candidate and human translatability.

Materials and methods

Radiochemistry of [³H]ORM-13070

[³H]ORM-13070 (1-{[(2S)-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}-4-[3-(methoxymethyl)pyridin-2-yl](³H₄)piperazine) was synthesized at Bayer AG by an iridium-catalyzed hydrogen-tritium exchange using Tamm’s catalyst ((1,5-cyclooctadiene){N-[2-(di-tert-butylphosphino)phenyl]-1,3,4,5-tetramethyl-1,3-dihydro-2H-imidazol-2-imine}iridium(I) tetrakis[3,5-bis(trifluoromethyl)phenyl]borate) (Supplemental Fig. 1).^14
–16

The tritiation was performed at ambient temperature and a tritium gas pressure of about 198 mbar. Purification of the tritiated material was performed by reversed phase (RP) chromatography. A total radioactivity amount of 9593 MBq was obtained, with a specific radioactivity of 7335 MBq/mg (2643 GBq/mmol). The identity was confirmed by ¹H-NMR, mass spectrometry and liquid chromatography (co-injection with reference material) (see Supplementary Material for details).

Radiochemistry of [¹¹C]ORM-13070

The reference compound ORM-13070 and its O-desmethyl precursor were synthesized by WuXi Apptech (Hubei, China) with chemical purities ≥99.3% (HPLC-UV) and assays for use ≥97.9%. All other chemicals were obtained from commercial sources.

In analogy to a literature procedure,⁵ [¹¹C]ORM-13070 was prepared at Invicro LLC by O-methylation of the O-desmethyl precursor with [¹¹C]-methyl triflate using a Siemens RDS Eclipse 111 cyclotron, TRACERlab™ FX2 MeI (GE Healthcare, Chalfont St Giles, UK) and Modular Lab (Eckert & Ziegler, Berlin, Germany) synthesis modules (Supplemental Fig. 2). In brief, [¹¹C]-methyl iodide, produced under standard conditions (reduction of [¹¹C]CO₂ using a Ni-Shimalite catalyst under hydrogen atmosphere at 350°C), was passed through a column containing silver trifluoromethanesulfonate. The generated [¹¹C]-methyl triflate was bubbled into the reactor vessel pre-charged with a solution of 0.9–1.1 mg desmethyl ORM-13070 precursor, anhydrous acetonitrile and tetrabutylammonium hydroxide (1 M in anhydrous MeOH) held at −5°C. The resulting mixture was heated for 3 min at 80°C, cooled to 40°C and purified by semi-preparative RP-HPLC. The PET tracer was isolated by solid phase extraction, formulated into 10% ethanolic saline, and finally passed through a 0.2 μm membrane filter for final sterilization. Decay-corrected radiochemical yields was, on average 17.3 ± 5% and the radioactivity of [¹¹C]ORM-13070 was 1494 ± 538 MBq at end of synthesis. Radiochemical purity exceeded 99% in all syntheses (n = 11). The average injected dose was 191 ± 22 MBq with an average injected mass of 1.15 ± 0.42 μg.

In vitro receptor autoradiography

Tissue preparation

Fresh-frozen tissue blocks containing the caudate brain region from three control human subjects were sourced from the Netherlands Brain Bank (subject demographics: 85 years female, 5:20 h post-mortem time; 95 years male, 7:15 h post-mortem time; 88 years male, 7:00 h post-mortem time). Tissue blocks were sectioned (20 μm thickness) using a cryostat (Bright Instruments Ltd., Huntingdon, UK) and mounted onto 1% gelatine subbed superfrost slides for autoradiography assays. Excess water was removed from the tissue sections by incubation with CaSO₄ for 1 hour at 4°C prior to storage at −80°C until used.

Autoradiography assay

Anatomically adjacent human caudate tissue sections (from n = 3 subjects) were brought to room temperature and pre-incubated in assay buffer (50 mM Tris, 140 mM NaCl, 1.5 mM MgCl₂, 5 mM KCl, 1.5 mM CaCl₂, pH 7.4, 23°C) for 15 minutes to remove any endogenous ligand. Sections were then incubated for 120 minutes at room temperature in assay buffer containing 0.5, 1, 5, 10 or 25 nM [³H]ORM-13070. The specific binding component was determined by incubating adjacent sections at room temperature with the radioligand in the presence of a saturating concentration of either unlabeled homologous blocking agent, 10 μM ORM-13070, or heterologous blocking agent, 10 μM BAY 292, to yield a measure of non-specific binding. Following incubation, the sections were washed twice in ice-cold buffer (50 mM Tris, 1.4 mM MgCl₂, pH 7.4, 4°C) and briefly submerged in water (reverse-osmosis filtered) to remove excess salts.

Autoradiography analysis

After drying, sections were apposed to a tritium-sensitive phosphor-imager plate for 7 days and analyzed using OptiQuant software (Perkin Elmer, USA, version 5.0.0.2). Regions of interest were manually drawn on each section to determine the binding expressed as digital light units (DLU)/mm². The specific binding signal was determined by subtracting the non-specific binding signal from the total binding signal. A tritiated tissue-equivalent microscale was apposed alongside the sections to allow for expression of binding as fmol/mg tissue. The specific binding window (expressed as percentage specific binding) was determined as the amount of specific binding as a percentage of the total binding signal. All graphs were produced using GraphPad Prism (v.6.07).

PET imaging in non-human primates

Study population

All animal experiments were conducted at Charles River Laboratories (Matawan, MI, USA), in full compliance with the Institutional Animal Care and Use Committee (IACUC) policies and procedures, which follow the recommendations of The Guide for the Care and Use of Laboratory Animals (“The Guide,” Institute of Laboratory Animal Resources, National Academy Press, Washington, D.C., 8^th Edition, 2011). Experiments were largely conducted under ARRIVE guidelines 2.0¹⁷ with the exception of subject randomization and blinding. Randomization was not employed as various drug doses and PET measures were compared to vehicle dose in the same subject, as PET signal under vehicle condition can vary across subjects. Blinding was not employed in study design and analysis as the study followed an adaptive design, with subsequent drug doses chosen dependent on previous results. Analysis methods for PET outcomes employed semi-automated methods to reduce analyst subjectivity. All in vivo experimentation was completed under an approved Charles River Laboratories IACUC animal use protocol (AUP). Two cynomolgus monkeys (Macaca fascicularis), one male (M1, 4.1 ± 0.3 kg) and one female (M2, 4.1 ± 0.2 kg), were scanned at baseline (n = 2) and at competition with BAY 292 (n = 8). One additional male subject (M3, 3.4 kg) received a baseline scan but was withdrawn from the study as placement of temporary venous access catheters for drug and tracer infusion proved to be unreliable, thus competition investigations were only conducted in the other two subjects. The primates ranged in age from two to five years old.

Study design

Initial scans were aimed at a high predicted receptor occupancy, with following target dose decisions being informed by previous scan results and adapted to target various occupancies to build the plasma exposure – receptor occupancy relationship. Constant plasma exposure of BAY 292 was maintained during the dynamic PET scans. As each monkey was scanned four to six times during the study, the study days for each monkey were scheduled at least two weeks apart to allow for recovery from anesthesia, blood volume recovery and drug clearance.

At baseline, the scans were performed in the presence of formulation vehicle, which was delivered to mimic the dose volume and infusion rate for the first competition experiment with BAY 292. For competition scans, formulated BAY 292 was administered via intravenous catheter starting at 30 min prior to tracer injection as a 2 min short infusion followed by a constant rate infusion (CRI) to the end of the scan (approx. 88 min) to ensure steady state plasma exposure during the PET scans (Figure 1). An exception was one experiment for which BAY 292 was administered via single rate CRI for 90 min starting at 30 min prior to tracer injection.

Figure 1.

Study Design of PET imaging study in cynomolgus monkeys. CRI: constant rate infusion; IV: intravenous

The study was designed to ensure that BAY 292 plasma concentrations were at steady state during [¹¹C]ORM-13070 scans. PET image acquisition began upon the start of 3 min (to allow for manual blood sampling) IV administration of [¹¹C]ORM-13070 and continued for 60 min.

Total doses administered and infusion rates for all BAY 292 competition scans are presented in Supplemental Tab. 1.

PET imaging

Animals were initially anesthetized with ketamine (5–10 mg/kg, IM) and atropine sulfate (0.025–0.05 mg/kg SC or IM). Once intubated, the animals were maintained on isoflurane/oxygen (1–3%) anesthesia for the duration of the scans. All brain imaging scans were acquired with the microPET Focus 220 scanner (Siemens Medical Systems, Knoxville, TN, USA). Following the intravenous injection of radiotracer dynamic emission data were collected continuously in list-mode for 60 min, and subsequently rebinned in a series of 21 dynamic 3D PET image volumes (6 × 0.5 min, 3 × 1 min, 2 × 2 min, 10 × 5 min). An x-ray CT transmission scan was performed using a CereTom® OTOscan (NeuroLogica, Danvers, MA, USA) to provide correction coefficients for photon attenuation in matter. The dynamic scan data series were subsequently reconstructed using standard filtered back projection with standard corrections for detector normalization, deadtime, randoms, scatter, attenuation, and radioactive decay provided by the camera manufacturer. A single 1.5T T1 MRI of the brain was acquired for each monkey using an Intera 1.5T^TM (Philips Medical Systems, Best, Netherlands) prior to the PET study for anatomical reference and image analysis.

Plasma radioactivity, metabolite analysis and protein binding

Starting at [¹¹C]ORM-13070 injection, arterial blood samples were drawn during the PET scan at 0.25, 0.75, 1.25, 2.25, 2.75, 3.25, 4, 5, 10, 15, 30, 45, and 60 min. Selected samples at 5, 15, 30, 45, and 60 min had a volume of 1.5 mL and were used for metabolite analysis to measure the fraction of unchanged [¹¹C]ORM-13070 in plasma (i.e., parent fraction) by HPLC. All samples were aliquoted (0.2 mL) and whole-blood and plasma separated by centrifugation (1300 g for 6 min at 4°C) were counted in a Wizard² gamma counter (PerkinElmer, Shelton, Connecticut, USA).

Plasma metabolite analysis was performed using an Agilent 1100 (Agilent Technologies, Santa Clara, CA, USA) equipped with a coincidence detector for radioactive detection and UV detection using a diode array detector set to 315 nm. Plasma (600 µL) was diluted with a solution of diluent (600 µL of 10 µg/mL unlabeled ORM-13070 standard in acetonitrile) to precipitate proteins, then centrifuged at 14,100 g for 3 min. The supernatant was removed, and both supernatant and pellet were analyzed in a Wizard² 10-well gamma counter (PerkinElmer, Shelton, Connecticut, USA). An appropriate volume to give approximately 60000 cpm per injection was injected onto a Phenomenex Luna 10 × 250 mm, 10 µm C18 column fitted with a 10 × 10 mm guard cartridge. Samples were analyzed using a 4.0 mL/min flow of 80:20:0.2 (v:v) ratio of methanol:water:triethylamine.

An ultrafiltration-based method was used for measuring the unbound portion (free fraction, f_p) of [¹¹C]ORM-13070 in plasma. A sample of [¹¹C]ORM-13070 (200 μCi) from the formulated dose, in a volume no greater than 0.25 mL, was spiked into 1–1.5 mL of a plasma sample taken shortly before injection and separated as described above. After 10 minutes of incubation at room temperature, the spiked plasma (0.25 mL) was loaded onto the reservoir of the Millipore Centrifree® Micropartition device (Millipore, Billerica, MA, USA) in duplicate and centrifuged at 1500 g for 20 minutes. The uncorrected f_p was determined as the ratio of the mean radioactivity concentration of the pass-through unbound [¹¹C]ORM-13070 in the filtrate to the mean total activity in plasma.

Determination of BAY 292 concentrations in plasma

In addition to the samples used to determine [¹¹C]ORM-13070 radioactivity concentration in plasma, blood samples (1.0 mL) were collected at −5 (pre-dose), 10, 30 (just before tracer administration), 60, 90 (end of scan), 120, and 180 min relative to start of BAY 292 administration. An additional sample was collected between 90 and 120 min immediately after the CT scan. Samples were collected with K₂-EDTA as anticoagulant and stored on ice during plasma processing. All PK samples and residual test article dosing formulation were stored frozen (−70 to −90°C). BAY 292 concentrations in plasma were quantified with bioanalytical HPLC-MS/MS methods (NorthEast BioAnalytical Laboratories LLC, Hamden, CT, USA).

Image analysis

Dynamic brain PET images were transferred and analyzed using the image processing PMOD software package v3.802 (PMOD Technologies, Zurich, Switzerland). The PET images were checked for motion, rigidly aligned to the MR image of the monkey’s brain and then spatially normalized to a common cynomolgus MRI template¹⁸ using a normalized mutual information algorithm.¹⁹ Regions of interest (ROIs) defined in the template space by an associated brain atlas¹⁸ were applied to the spatially normalized PET images to compute time-activity curves (TACs, in kBq/cm³) which included caudate nucleus (0.96 cm³), putamen (1.34 cm³), ventral striatum (0.24 cm³), pallidum (0.35 cm³), and cerebellar cortex (3.81 cm³). ROIs used for analysis are illustrated in Supplemental Fig. 3. Brain TACs and the arterial input function (AIF) were used for quantification with compartmental modeling. Images and TACs were presented in SUV units (g/mL) by normalizing to the body weight and the injected activity.

Kinetic analyses and occupancy determination

Regional brain TACs of [¹¹C]ORM-13070 were modeled with multilinear analysis (MA1) model for reversible tracers²⁰ implemented in PMOD kinetic toolbox (PKIN), to estimate the total volume of distribution, V_T (mL/cm³) in each brain region using AIF. MA1 model is described by the following equation:

C_{T} (t) = - \frac{V_{T}}{b} \int_{0}^{t} C_{P} (τ) d τ + \frac{1}{b} \int_{0}^{t} C_{T} (τ) d τ

where C_T(t) represents the tissue time-activity curve, C_P(t) the metabolite corrected plasma activity (or AIF), and b the y-intercept of the Logan plot,²¹ which becomes constant after an equilibration time t*. In the PKIN toolbox, the bilinear regression is performed using a singular value decomposition. The results are the two coefficients V_T/b and b, from which V_T can easily be derived. The cutoff time t* was set to 20 min, based on a joint fit of basal ganglia regions at baseline.

V_T estimated with MA1 was compared at baseline with V_T estimated using a 1-tissue and 2-tissue compartmental models (1TC and 2TC).²² Goodness-of-fit by 1TC and 2TC was evaluated using the Akaike information criterion (AIC; a smaller AIC indicates a more appropriate model). The global α_2C occupancy by BAY 292 was estimated using a modified Lassen plot, a.k.a. occupancy plot with $V_{T}^{Baseline} - V_{T}^{Drug}$ on the y-axis and $V_{T}^{Baseline}$ on the x-axis.²³ $V_{T}^{Baseline}$ is the V_T at baseline, and $V_{T}^{Drug}$ is the V_T following competition with BAY 292. The brain α_2C occupancy is given by the slope of the linear regression, and the non-displaceable distribution volume, V_ND, is given by the x-intercept. Due to low signal-to-noise elsewhere, of the potential α_2C binding regions only V_T of basal ganglia (caudate nucleus, putamen, ventral striatum, and pallidum) were used to estimate occupancy. The relationship between the fractional occupancy at α_2C sites computed from [¹¹C]ORM-13070 competition studies and plasma concentration of BAY 292 were investigated with a single specific binding site (E_max) model with a fixed Hill slope, h, of 1 and maximum occupancy, ${Occ}^{\max}$ constrained to 100%.

Occ = \frac{{Occ}^{\max} \times X^{h}}{X^{h} + {E C}_{50}^{h}}

where Occ is the measured occupancy, X the BAY 292 average plasma concentration (in ng/mL) as C_30–90, measured during imaging (30 to 90 min from the start of BAY 292 administration).

As alternative, non-invasive approach, not requiring arterial sampling, binding potentials (BP_ND) in α_2C-rich regions were estimated using a simplified reference tissue method (SRTM),²⁴ by assuming cerebellar cortex was devoid of α_2C receptors and could be used as a reference region. To estimate occupancy a modified occupancy plot approach was used, in which V_T was replaced by BP_ND and x-intercept was constrained to zero.

Results

In vitro receptor autoradiography

In vitro autoradiography experiments revealed a specific binding signal in the human caudate with 0.5–25 nM [³H]ORM-13070 using the homologous blocking agent (ORM-13070) to determine the non-specific binding (Figure 2, Table 1). The chemotype distinctive heterologous blocking agent, BAY 292, showed similar specific binding signal when used to measure non-specific binding, indicating that it shares the same binding site as ORM-13070 and supporting selectivity of the compound to α_2C receptors.

Figure 2.

In vitro autoradiography of [³H]ORM-13070 binding in human caudate. (a) Representative autoradiograms of [³H]ORM-13070 binding in human caudate tissue under TOP: total binding conditions, MIDDLE: non-specific binding as determined with 10 µM unlabeled ORM-13070, BOTTOM: non-specific binding as determined with 10 µM BAY 292. Specific binding of [³H]ORM-13070 in control human caudate (n = 3, mean ± SD) expressed as (b) fmol/mg tissue and (c) percentage of total binding. Normal distribution was confirmed by the Shapiro-Wilk test.

Table 1.

Specific binding of [³H]ORM-13070 in control human caudate sections using homologous ORM-13070 and heterologous BAY 292 as blocking agents to determine non-specific binding.

[³H]ORM-13070 Concentration		ORM-13070		BAY 292
[³H]ORM-13070 Concentration		Specific binding	Specific binding window^a	Specific binding	Specific binding window^a
[nM]	Subject ID	[fmol/mg tissue]	[%]	[fmol/mg tissue]	[%]
0.5	1	24.0	114	19.7	93
	2	50.2	111	47.0	104
	3	21.1	108	17.1	88
	Average (±SD)	31.8 (16.0)	111 (3.0)	27.9 (16.6)	95 (8.2)
1	1	20.4	80	13.3	52
	2	55.6	94	48.1	81
	3	30.5	90	27.5	81
	Average (±SD)	35.5 (18.1)	88.0 (7.2)	29.6 (17.5)	71.3 (16.7)
5	1	59.7	67	23.3	26
	2	129.5	89	63.3	44
	3	75.5	69	42.5	39
	Average (±SD)	88.2 (36.6)	75.0 (12.2)	43.0 (20.0)	36.3 (9.3)
10	1	108.6	53	21.8	11
	2	157.2	59	94.4	35
	3	89.3	37	113.9	47
	Average (±SD)	118.4 (35.0)	49.7 (11.4)	76.7 (48.5)	31 (18.3)
25	1	160.8	46	0	0
	2	347.4	69	195.6	39
	3	170.1	37	150.1	32
	Average (±SD)	226.1 (105.2)	50.7 (16.5)	115.2 (102.4)	23.7 (20.8)

Binding expressed as fmol/mg tissue and % specific binding. Values are based on the binding in sections from three control human subjects. Data in bold (specific binding) expressed as mean (±SD, n = 3 subjects).

The specific binding window indicates the proportion of overall binding (total) that is displaceable by unlabeled ORM-13070 or BAY 292. Values ≥100% reflect full displacement of the radioligand but demonstrate the limit of assay sensitivity at the lower concentrations used.

PET imaging in non-human primates

[¹¹C]ORM-13070 arterial blood measurements

The plasma to whole blood radioactivity concentration ratio (10–60 min post tracer injection) was 1.2 ± 0.1 (mean ± SD, n = 10, see also Supplemental Fig. 4 C). [¹¹C]ORM-13070 metabolized with 39 ± 6% and 19 ± 4% intact tracer remaining at 15 and 60 min post-injection, respectively (Supplemental Fig. 4A). BAY 292 administration did not majorly impact tracer metabolism. For AIF generation parent fraction values were fitted to a 2-exponential function. Plasma free fraction, f_P was 6.5 ± 1.0% with no effect attributed to BAY 292 or major difference between the subjects observed (Supplemental Fig. 4B).

[¹¹C]ORM-13070 brain distribution and kinetics

[¹¹C]ORM-13070 SUV images averaged over 20–60 min post tracer injection acquired at baseline and competition with different doses of BAY 292 are presented in Figure 3. Images showed [¹¹C]ORM-13070 highest, in order, brain uptake values in the putamen, caudate nucleus, ventral striatum, and pallidum, low levels in other brain regions, and lowest uptake in cerebellar cortex. A dose-dependent reduction in the image intensity could be observed in all brain regions for images acquired in competition with BAY 292. An exception was the competition experiment at highest infusion rate (6.45 mg/kg total dose) with animal M1 (Figure 3(a), bottom row) for which the SUV 20-60 min was elevated compared to competition with BAY 292 infused at the lower rates, which can be explained by an elevation of the corresponding arterial blood concentrations of the tracer (data from this dose was not excluded when deriving the EC₅₀).

Figure 3.

[¹¹C]ORM-13070 images of the two monkey subjects (a) M1, and (b) M2 acquired at baseline and competition with BAY 292 administered as IV infusion at total doses of 0.3, 0.35, 0.37, 0.6, 0.75 (n = 2), 2.25, and 6.45 mg/kg. PET images (SUV) were averaged from 20 to 60 min post tracer injection. All images were normalized to a common cynomolgus MRI brain template. Each monkey’s normalized MRI is shown in the top row.

An example of [¹¹C]ORM-13070 TACs obtained in one monkey (M2) from relevant brain regions (caudate nucleus, putamen, ventral striatum, pallidum, and cerebellar cortex), acquired at baseline and competition with BAY 292 is shown in Figure 4.

Figure 4.

(a, b) Examples of regional time activity curves from one monkey (M2) during the PET scan, (c) BAY 292 plasma concentration profiles, and (d) α_2CR occupancy vs. BAY 292 plasma concentration. (a) baseline and (b) competition with BAY 292 0.75 mg/kg in the caudate nucleus (solid triangles), putamen (solid circles), ventral striatum (open triangles), pallidum (solid squares) and cerebellar cortex (open circles). Solid lines correspond to the MA1 fits.The arrow in subplot C indicates start of PET tracer injection.

[¹¹C]ORM-13070 presented a peak whole brain uptake up to ∼4.5 SUV (up to ∼7 SUV in putamen) at 5 min post injection accompanied by a clear washout consistent with reversible kinetics. Examination of TACs acquired at different doses of BAY 292 indicated a dose dependent increase in the washout of [¹¹C]ORM-13070 due to competition with BAY 292, with nearly complete blockade of displaceable binding of [¹¹C]ORM-13070 being achieved at the highest infusion rates. These observations are consistent with the notion that BAY 292 bound to the α_2CR in a dose dependent manner.

[¹¹C]ORM-13070 quantitation and estimation of BAY 292 EC₅₀

Initial evaluation of 1TC and 2TC models revealed that none of them was optimal. Based on the AIC, the 2TC model was overall better suited than the 1TC model to describe the data (see also Supplemental Fig. 5A). However, 2TC occasionally did not provide reliable V_T values, with some estimates having large standard errors (>25%). MA1 model produced good fits, with V_T values in good agreement with both the 1TC model (y = 1.01x–0.46, r = 0.97) and 2TC model (y = 1.05x–0.14, r = 0.96) (Supplemental Fig. 5B), as shown by data at baseline. Overall, the MA1 model was well suited to describe the [¹¹C]ORM-13070 brain data and was more robust in parameter estimates than 2TC, thus was preferred to estimate V_T. Regional V_T estimated with MA1 at baseline and during administration of BAY 292 are listed in Table 2. A complete list of V_T values, which includes extra-striatal cortical regions and white matter is provided in Supplemental Tab. 3.

Table 2.

Regional distribution volume, V_T (mL/cm³), of [¹¹C]ORM-13070 at baseline and competition with BAY 292.

Monkey	M1 (male)						M2 (female)
BAY 292 Dose [mg/kg]	bsl^a	0.3^b	0.35	0.75	2.25	6.45	bsl^a	0.37	0.6	0.75
V_T Caudate Nucleus	8.19	8.63	7.30	6.09	5.44	5.51	7.59	6.34	5.96	5.89
V_T Putamen	9.03	9.34	7.37	6.30	5.66	5.46	8.21	6.74	6.11	6.05
V_T Ventral Striatum	7.35	8.12	6.36	5.87	5.07	5.19	7.11	6.25	5.61	5.81
V_T Pallidum	6.77	7.93	6.69	5.60	5.72	5.58	5.82	6.14	5.95	5.97
V_T Cerebellar Cortex	5.65	6.45	5.23	4.29	4.70	4.78	4.30	4.73	4.89	5.20

bsl = baseline scan.

Only one constant rate infusion was used.

Baseline regional V_T ranged from 8–9 mL/cm³ in putamen to ∼4.5–5.5 mL/cm³ in cerebellar cortex and were generally consistent with the literature describing adrenergic-α_2CR density in the primate brain.⁶ [¹¹C]ORM-13070 presented relatively low signal-to-noise properties at baseline ( $V_{T}^{Putamen} / V_{T}^{Cerebellar Cortex}$ ∼1.6–1.9) with a relatively reliable signal expected only in the α_2C-rich regions of basal ganglia (putamen >caudate nucleus > ventral striatum > pallidum). Overall α_2C-rich regions showed a reduction in V_T because of competition with BAY 292 (between 18% and 40% in putamen relative to baseline). An exception was BAY 292 0.3 mg/kg (M1) which presented a global (brain wide) larger V_T than baseline.

Occupancy plots used to estimate the α_2C occupancy from the slope of linear regression as well as the fractional α_2C RO values are shown in Figure 5. The α_2C-rich regions and the cerebellar cortex were initially included in the analysis. Cerebellar cortex V_T appeared to be consistently an outlier with respect to linear regression, so it was excluded from analysis. BAY 292 occupancy estimates ranged between 37.2% and 99.3% for monkey M1, and between 77.6% and 97.9% for monkey M2 (Figure 5(a) and (b)).

Figure 5.

Occupancy plots of the two monkey subjects M1 (a, c), and M2 (b, d) at eight doses of BAY 292 using only V_T data from α_2C-rich regions (a, b), or using V_T data from α_2C-rich regions + cerebellar cortex (c, d). Fractional occupancy values (slope), and V_ND (x-int) are displayed in the inset tables.

Plasma concentration profiles of BAY 292 shown in Figure 4(c) indicate that a steady state in drug concentration was achieved over the duration of all competition PET scans except at 0.3 mg/kg dose administered to monkey M1, for which a single rate BAY 292 infusion was used. Plasma levels were largely in agreement with ranking dose levels except at 0.37 mg/kg dose given to monkey M2, which appears lower than expected when compared to plasma levels at other doses. The α_2C occupancy estimates were generally consistent with the average plasma levels during imaging. The relationship between occupancy and BAY 292 plasma concentration is illustrated in Figure 4(d). Despite the limited number of data points at low occupancy levels due to increasing noise at the lower end of the curve, based on the E_max model fit (r² = 0.47) the effective concentration, EC₅₀, of BAY 292 for α_2C was estimated to be 33.39 ± 11.91 ng/mL (95% CI = 5.23–61.55), n = 8.

Evaluation of cerebellar cortex as a reference region

To potentially avoid invasive arterial blood sampling and possibly reduce the uncertainty in drug EC₅₀ estimates, the use of cerebellar cortex as reference region was investigated. At competition scans with BAY 292 changes in V_T of −21% to 24% relative to baseline were also observed in the cerebellar cortex, expected to be devoid of α_2C receptors and candidate reference region. Cerebellar cortex V_T was not correlated with the plasma free fraction f_P. By including cerebellar cortex V_T in the analysis BAY 292 occupancy estimates were biased by ∼−20%, ranging between 19.4% and 82.5% for monkey M1, and between 54.1% and 81.9% for monkey M2 (Figure 5(c) and (d)). Furthermore, EC₅₀ estimates were 108.4 ng/mL, ∼3-fold larger than EC₅₀ based on V_T of α_2C-rich regions (data not shown).

[¹¹C]ORM binding potentials, BP_ND, were also estimated without arterial blood directly from SRTM and the cerebellar cortex as a reference region. Regional BP_ND values at baseline and competition with BAY 292 can be found in Supplemental Tab. 2. The available specific signal was low, with BP_ND in α_2C-rich regions from 0.3 to 0.8 (M1), and 0.4 to 1.0 (M2). Occupancy values (Supplemental Tab. 2) were biased by −20%, with maximum of 80.8% at the highest dose, similarly to V_T based results. The E_max model applied to plasma-occupancy data with occupancy estimated using BP_ND resulted in EC₅₀ estimates that were ∼6-fold larger than EC₅₀ based on V_T of α_2C-rich regions (data not shown).

As an exercise, the E_max model was applied without constraining Occ^max to 100%. As a result, the EC₅₀ from using V_T of α_2C-rich regions suffered little change and was estimated to be 30.8 ng/mL, while the EC₅₀ from using either V_T of α_2C-rich regions + cerebellar cortex, or BP_ND were estimated to be either ∼2-fold, or ∼3-fold larger, respectively.

Discussion

In this study we evaluated the utility of [¹¹C]ORM-13070 PET to quantify brain α_2CR density and evaluate its occupancy by a novel drug candidate. We used the α_2CR selective antagonist BAY 292 as a pharmacological challenge to quantify the displaceable binding component of [¹¹C]ORM-13070 and evaluated the relationship between the plasma concentration of BAY 292 and α_2CR occupancy. BAY 292 has been shown to be selective for the α_2CR (unpublished, internal data), and in vitro autoradiography confirmed that it bound to the same binding site as [³H]ORM-13070 in human caudate tissue.

Previous in vivo evaluation of [¹¹C]ORM-13070 in non-human primates⁶ demonstrated reversible kinetics, with highest binding in the striatum (putamen, caudate, ventral striatum, and pallidum) and low levels elsewhere, with the cerebellar cortex demonstrating lowest binding, consistent with the previously described distribution of the α_2CR in rodents and humans.^25
–27

Previous evaluations of [¹¹C]ORM-13070 in the human brain^9
–11 conducted full quantification (including metabolite corrected arterial plasma input function) under baseline conditions, however evaluation of the [¹¹C]ORM-13070 binding following the administration of blocking compounds was conducted using models that utilized the cerebellar cortex as a reference tissue, making the explicit assumption that the cerebellar V_T of [¹¹C]ORM-13070 is an accurate representation of its non-displaceable binding (V_ND) in the α_2C-rich regions. While the cerebellar cortex has minimal α_2CR expression and should be a viable reference tissue for [¹¹C]ORM-13070, this assumption has not been tested explicitly until now. Indeed, the findings of α_2CR occupancies in these studies indicated that the maximal achievable occupancies were significantly lower than 100%. While several biologically plausible explanations are consistent with these findings, a violation of the assumptions inherent to the use of cerebellar cortex as a reference region is one that should be examined.

We found the regional binding of [¹¹C]ORM-13070 to be consistent with previous reports.^9
–11 The α_2C-rich regions in basal ganglia were the only ones that provided suitable signal-to-noise ratios, and thus the analyses were confined to these regions and the cerebellar cortex. A dose dependent decrease in [¹¹C]ORM-13070 binding was observed after BAY 292 administration, consistent with BAY 292 crossing the blood-brain barrier and binding to α_2CR. We initially used the regional V_T for α_2C-rich regions and the cerebellar cortex to evaluate α_2CR occupancy using the occupancy plot²³ and the resulting occupancy curves suggested a maximal occupancy significantly lower than 100%. This finding is consistent with previous studies examining the occupancy of atipamezole and ORM-12741.^9,11 Visual inspection of the occupancy plots (Figure 5) indicated that the cerebellar cortex appeared to lie off the linear regression plot of the other regions, consistent with the notion that the cerebellar binding component that cannot be displaced by BAY 292 is significantly lower than that in the α_2C-rich regions. If this were the case, it would violate one of the assumptions of the occupancy plot (that the non-displaceable binding be equal in all regions evaluated) and would lead to an underestimation of the maximal achievable occupancy and/or a bias in the estimation of the EC₅₀. Removal of the cerebellar cortex from the list of regions used to evaluate occupancy via the occupancy plot provided better linear fits, higher levels of occupancy and higher estimates of non-displaceable binding (V_ND) in the α_2C-rich regions. The use of these occupancy data in conjunction with the plasma concentration of BAY 292 provided a maximal occupancy of 100%. By comparison, the inclusion of cerebellar cortex, whether in the arterial blood-based analysis using V_T or in the non-invasive analysis using BP_ND, provided a maximal occupancy of ∼80%, while the resulting EC₅₀ was determined to be about 3- to 6-fold higher.

The reasons for the observed regional differences in non-displaceable binding cannot be conclusively established with the data from our study. While [¹¹C]ORM-13070 binding to another target for which BAY 292 has no affinity could produce the results we are seeing, no evidence for such a target is indicated by the examination of the available data on ORM-13070 selectivity. The fact that similar features are seen with several different blocking compounds (BAY 292, atipamezole and ORM-12741) would make this possibility even more unlikely. A more likely scenario is a difference in the “non-specific” binding between the cerebellar cortex and α_2C-rich regions, possibly attributed to different proportions of white and grey matter in the two structures. While the cerebellar cortex is often used as a reference region for PET ligands with targets absent from the cerebellar cortex, no systematic evaluation of the levels of non-specific binding between the cerebellar cortex and basal ganglia has been conducted. Past experience indicates that any differences in non-specific binding are likely to be small, and for ligands with a high BP_ND such differences are likely to be inconsequential. However, for ligands with low BP_ND, such as [¹¹C]ORM-13070, even small differences in non-specific binding can produce substantial biases.

Some limitations of our study are discussed below. We observed an occupancy result in one of our scans (0.37 mg/kg data point) that appears to be out of pattern with other data points. We could not find an objective reason for such a divergence, and therefore have included it in the final analysis. Exclusion of this data point would cause a right shift of E_max fit resulting in an EC₅₀ of 51.27 ± 12.03 ng/mL (95% CI = 21.83–80.71) and an improved goodness of fit (r² = 0.81). The overall conclusions of the study would remain similar.

The use of anesthesia in preclinical brain PET studies can have an impact on receptor binding and thus also represents a main confounding factor for proper translational understanding of animal models, as clinical PET studies are typically performed without the use of anesthesia.²⁸ Despite the considerable research progress that has been made over the past years towards motion tracking with subsequent motion correction reconstruction, this technique is not yet readily available to most research centers so that anesthetized animals are still most commonly used in the majority of studies conducted. Although interactions between anesthesia and receptor binding cannot be ruled out completely, literature evidence does not provide hints on marked differences for noradrenergic transporters in primates.^29,30 In addition, as a PET study usually provides relative measurements, the integrity of the study itself is not considered as biased by anesthetic effects.

Finally, the low plasma free fraction (f_p) of ORM-13070 (∼6–7%, determined in this study for informative purposes only) may impact its application in PET studies not using a reference region, as accurate determination of individual scan f_p may not be feasible. However, a number of tracers with an even lower free fraction are used successfully, with the understanding that either f_p is assumed to be unaffected by experimental conditions, or it is assessed on a group rather than an individual level.^31
–33

In summary, despite the limitations of this tracer (low specific binding signal, low free fraction, imperfect reference region), and in the absence of superior alternatives, this study demonstrated the utility of [¹¹C]ORM-13070 as a PET-radioligand for the study of α_2CR in the non-human primate brain, paving the way for its use in BAY 292 clinical studies. It was also observed that previously described models for RO calculation using the cerebellar cortex as a reference region for ORM-13070^10,11 may lead to bias, and methods avoiding its use should be considered preferable, at least for datasets revealing low signal-to-noise-ratios or binding potentials, as observed in this study. Finally, a dose dependent increase in RO after BAY 292 administration was observed, confirming BBB penetration and target engagement of the drug candidate.

Supplemental Material

sj-pdf-1-jcb-10.1177_0271678X241291949 - Supplemental material for Preclinical in vitro and in vivo evaluation of [¹¹C]ORM-13070 as PET ligand for alpha-2C adrenergic receptor occupancy using PET imaging in non-human primates

Supplemental material, sj-pdf-1-jcb-10.1177_0271678X241291949 for Preclinical in vitro and in vivo evaluation of [¹¹C]ORM-13070 as PET ligand for alpha-2C adrenergic receptor occupancy using PET imaging in non-human primates by Isabel Piel, Cristian C Constantinescu, David de la Puente Bethencourt, David R Bonsall, Eugenii A Rabiner, Kenneth R Zasadny, Amy Llopis Amenta, Lisa A Wells, Thorsten Poethko, Wolfgang Prange and Martina Delbeck in Journal of Cerebral Blood Flow & Metabolism

Footnotes

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Acknowledgements

The brain samples were obtained from The Netherlands Brain Bank, Netherlands Institute for Neuroscience, Amsterdam. All material has been collected from donors for or from whom a written informed consent for a brain autopsy and the use of the material and clinical information for research purposes had been obtained by the NBB. The authors thank all scientists from the different laboratories who contributed to this study: Shafina Khatun (Invicro LLC, London, UK) for tissue preparations and Giulia Boscutti (Invicro LLC, London, UK) for supporting the [¹¹C]-radiochemistry, Wendy Marriner, Esteban Oyarzabal (Charles River Laboratories, Matawan, MI, USA) and Ron Mays (NorthEast BioAnalytical Laboratories LLC, Hamden, CT, USA). The following Bayer AG colleagues also receive special thanks: Simon Rataj and Leon Selent for synthesizing [³H]ORM-13070, Dieudonné Tshitenge for NMR analysis of [³H]ORM-13070, Christoph Thiel for supporting this study with PK predictions and Nicola Busch for editorial support during the preparation of this manuscript.

Declaration of conflicting interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: DPB, IP, TP and WP are employees of Bayer AG and may own shares or share options. MD was employee of Bayer AG at the time of conducting the study and data analysis. The study was funded by Bayer AG.

ALA, CCC, DRB, EAR, KRZ, LAW are full-time employees of Invicro LLC.

Authors’ contributions

Participated in research design: ALA, DPB, DRB, CCC, MD, IP, EAR, WP, LAW, KRZ

Conducted experiments: DRB, TP

Performed data analysis: DPB, DRB, CCC, MD, IP, TP, EAR, WP, LAW, KRZ

Wrote or contributed to the writing of the manuscript: ALA, DPB, DRB, CCC, MD, IP, TP, EAR, WP, LAW, KRZ

Supplementary material

Supplemental material for this article is available online.

ORCID iDs

Isabel Piel

Amy Llopis Amenta

References

Hein

Altman

Kobilka

BK.

Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 1999; 402: 181–184.

Sallee

Connor

Newcorn

JH.

A review of the rationale and clinical utilization of alpha2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders. J Child Adolesc Psychopharmacol 2013; 23: 308–319.

Alluri

Kim

Volkow

, et al. PET radiotracers for CNS-adrenergic receptors: developments and perspectives. Molecules 2020; 25: 09–10.

Kawamura

Akiyama

Yui

, et al. In vivo evaluation of limiting brain penetration of probes for alpha(2C)-adrenoceptor using small-animal positron emission tomography. ACS Chem Neurosci 2010; 1: 520–528.

Arponen

Helin

Marjamaki

, et al. A pet tracer for brain alpha2c adrenoceptors, (11)C-ORM-13070: radiosynthesis and preclinical evaluation in rats and knockout mice. J Nucl Med 2014; 55: 1171–1177.

Finnema

Hughes

Haaparanta-Solin

, et al. Amphetamine decreases alpha2C-adrenoceptor binding of [11C]ORM-13070: a PET study in the primate brain. Int J Neuropsychopharmacol 2014; 18: 12–19.

Luoto

Suilamo

Oikonen

, et al. (11)C-ORM-13070, a novel PET ligand for brain alpha(2)C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men. Eur J Nucl Med Mol Imaging 2014; 41: 1947–1956.

clinicaltrials.gov. NCT00735774 and NCT00829907.

Lehto

Hirvonen

Johansson

, et al. Validation of [(11)C]ORM-13070 as a PET tracer for alpha2c-adrenoceptors in the human brain. Synapse 2015; 69: 172–181.

10.

Lehto

Johansson

Vuorilehto

, et al. Sensitivity of [(11)C]ORM-13070 to increased extracellular noradrenaline in the CNS – a PET study in human subjects. Psychopharmacology (Berl) 2015; 232: 4169–4178.

11.

Shahid

Rinne

Scheinin

, et al. Application of the PET ligand [(11)C]ORM-13070 to examine receptor occupancy by the alpha(2C)-adrenoceptor antagonist ORM-12741: translational validation of target engagement in rat and human brain. EJNMMI Res 2020; 10: 152.

12.

Scheinin

Lehto

Johansson

, et al. Imaging of alpha2C-adrenoceptors in the living brain: a method to monitor noradrenaline release? Springerplus 2015; 4: L20.

13.

Lehto

Virta

Oikonen

, et al. Test-retest reliability of (11)C-ORM-13070 in PET imaging of alpha2C-adrenoceptors in vivo in the human brain. Eur J Nucl Med Mol Imaging 2015; 42: 120–127.

14.

Becker

Bockfeld

Tamm

Front cover picture: an update on phosphine-imidazolin-2-imine iridium(I) catalysts for hydrogen isotope exchange (Adv. Synth. Catal. 3/2023). Adv Synth Catal 2023; 365: 269–269.

15.

Valero

Burhop

Jess

, et al. Evaluation of a P,N-ligated iridium(I) catalyst in hydrogen isotope exchange reactions of aryl and heteroaryl compounds. J Labelled Comp Radiopharm 2018; 61: 380–385.

16.

Valero

Mishra

Blass

, et al. Comparison of iridium(I) catalysts in temperature mediated hydrogen isotope exchange reactions. ChemistryOpen 2019; 8: 1183–1189.

17.

NC3Rs. ARRIVE guidelines, https://arriveguidelines.org/.

18.

Ballanger

Tremblay

Sgambato-Faure

, et al. A multi-atlas based method for automated anatomical Macaca fascicularis brain MRI segmentation and PET kinetic extraction. Neuroimage 2013; 77: 26–43.

19.

Studholme

Hill

DLG

Hawkes

DJ.

An overlap invariant entropy measure of 3D medical image alignment. Pattern Recognition 1999; 32: 71–86.

20.

Ichise

Toyama

Innis

, et al. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab 2002; 22: 1271–1281.

21.

Logan

Fowler

Volkow

, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990; 10: 740–747.

22.

Gunn

Cunningham

VJ.

Positron emission tomography compartmental models. J Cereb Blood Flow Metab 2001; 21: 635–652.

23.

Cunningham

Rabiner

Slifstein

, et al. Measuring drug occupancy in the absence of a reference region: the lassen plot re-visited. J Cereb Blood Flow Metab 2010; 30: 46–50.

24.

Lammertsma

Hume

SP.

Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4: 153–158.

25.

Fagerholm

Rokka

Nyman

, et al. Autoradiographic characterization of alpha(2C)-adrenoceptors in the human striatum. Synapse 2008; 62: 508–515.

26.

MacDonald

Kobilka

Scheinin

Gene targeting–homing in on alpha 2-adrenoceptor-subtype function. Trends Pharmacol Sci 1997; 18: 211–219.

27.

Scheinin

Lomasney

Hayden-Hixson

, et al. Distribution of alpha 2-adrenergic receptor subtype gene expression in rat brain. Brain Res Mol Brain Res 1994; 21: 133–149.

28.

Miranda

Bertoglio

Stroobants

, et al. Translation of preclinical PET imaging findings: challenges and motion correction to overcome the confounding effect of anesthetics. Front Med (Lausanne) 2021; 8: 753977.

29.

Alstrup

Smith

DF.

Anaesthesia for positron emission tomography scanning of animal brains. Lab Anim 2013; 47: 12–18.

30.

Zeng

Mun

Jarkas

, et al. Synthesis, radiosynthesis, and biological evaluation of carbon-11 and fluorine-18 labeled reboxetine analogues: potential positron emission tomography radioligands for in vivo imaging of the norepinephrine transporter. J Med Chem 2009; 52: 62–73.

31.

Normandin

Zheng

M-Q

Lin

K-S

, et al. Imaging the cannabinoid CB1 receptor in humans with [11C] OMAR: Assessment of kinetic analysis methods, test–retest reproducibility, and gender differences. J Cereb Blood Flow Metab 2015; 35: 1313–1322.

32.

Salinas

Lohith

Purohit

, et al. Test-retest characteristic of [(18)F]MK-6240 quantitative outcomes in cognitively normal adults and subjects with Alzheimer's disease. J Cereb Blood Flow Metab 2020; 40: 2179–2187.

33.

Sanabria-Bohorquez

Hamill

Goffin

, et al. Kinetic analysis of the cannabinoid-1 receptor PET tracer [(18)F]MK-9470 in human brain. Eur J Nucl Med Mol Imaging 2010; 37: 920–933.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.01 MB

Preclinical in vitro and in vivo evaluation of [ 11 C]ORM-13070 as PET ligand for alpha-2C adrenergic receptor occupancy using PET imaging in non-human primates

Abstract

Keywords

Introduction

Materials and methods

Radiochemistry of [3H]ORM-13070

Radiochemistry of [11C]ORM-13070

In vitro receptor autoradiography

Tissue preparation

Autoradiography assay

Autoradiography analysis

PET imaging in non-human primates

Study population

Study design

PET imaging

Plasma radioactivity, metabolite analysis and protein binding

Determination of BAY 292 concentrations in plasma

Image analysis

Kinetic analyses and occupancy determination

Results

In vitro receptor autoradiography

PET imaging in non-human primates

[11C]ORM-13070 arterial blood measurements

[11C]ORM-13070 brain distribution and kinetics

[11C]ORM-13070 quantitation and estimation of BAY 292 EC50

Evaluation of cerebellar cortex as a reference region

Discussion

Supplemental Material

sj-pdf-1-jcb-10.1177_0271678X241291949 - Supplemental material for Preclinical in vitro and in vivo evaluation of [11C]ORM-13070 as PET ligand for alpha-2C adrenergic receptor occupancy using PET imaging in non-human primates

Footnotes

Funding

Acknowledgements

Declaration of conflicting interests

Authors’ contributions

Supplementary material

ORCID iDs

References

Supplementary Material

Radiochemistry of [³H]ORM-13070

Radiochemistry of [¹¹C]ORM-13070

[¹¹C]ORM-13070 arterial blood measurements

[¹¹C]ORM-13070 brain distribution and kinetics

[¹¹C]ORM-13070 quantitation and estimation of BAY 292 EC₅₀

sj-pdf-1-jcb-10.1177_0271678X241291949 - Supplemental material for Preclinical in vitro and in vivo evaluation of [¹¹C]ORM-13070 as PET ligand for alpha-2C adrenergic receptor occupancy using PET imaging in non-human primates